Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®
Status:
Completed
Trial end date:
2020-09-11
Target enrollment:
Participant gender:
Summary
This is a single center, randomized, blind, parallel controlled clinical trial. The primary
objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2
monoclonal antibody injection GB221 in comparison with Herceptin ® in Chinese healthy adult
volunteers. The main aim is to study the pharmacokinetic similarity between GB221 and
Herceptin ®.